BiotechTube
Nerviano Medical Sciences

Nerviano Medical Sciences

Nerviano, Italy· Est.
nervianoms.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $50M

Overview

Nerviano Medical Sciences is a specialized oncology-focused CRO with a strong legacy in drug discovery, originally built on the foundation of the former Pharmacia research center. It offers integrated services across the entire drug development value chain, including medicinal chemistry, biology, DMPK, and clinical operations, with a particular strength in kinase inhibitors. As a private company, its business model is based on providing fee-for-service and collaborative R&D, positioning it as a strategic partner for clients seeking deep oncology expertise.

Oncology

Technology Platform

Integrated oncology drug discovery and development platforms encompassing target biology, medicinal chemistry (specialty in kinase inhibitors), biologics/antibody discovery, DMPK, toxicology, and clinical operations.

Funding History

2
Total raised:$50M
Series B$30M
Grant$20M

Opportunities

The growing trend of pharmaceutical outsourcing and the sustained high investment in oncology R&D present a significant market opportunity.
NMS can capitalize on its integrated, specialized model to attract virtual biotechs and large pharma partners seeking deep oncology expertise.
Expanding service offerings into new modalities like cell therapy or targeted protein degradation could drive future growth.

Risk Factors

The company faces intense competition from larger, global CROs and niche players, which could lead to pricing pressure.
Dependency on a limited number of major clients creates concentration risk.
Its specialized focus on oncology also makes it vulnerable to shifts in therapeutic area popularity or R&D funding priorities.

Competitive Landscape

NMS competes in the crowded CRO market, differentiated by its deep, integrated focus on oncology. Key competitors include large global CROs (e.g., IQVIA, LabCorp, PPD) with broader but less specialized capabilities, and other oncology-focused service providers like Crown Bioscience and Eurofins Discovery. Its legacy from a major pharma research center provides a unique credibility in kinase biology and drug discovery.

More companies in Small Molecule Drugs →More companies in Italy →